Krystal posts early proof-of-concept for cystic fibrosis gene therapy

Krystal reported early proof‑of‑concept clinical signals for its cystic fibrosis gene therapy program, according to a BioCentury clinical report summarizing recent trial updates. The company’s early human data indicate activity on key biomarkers and support further development. The results are preliminary and limited in scale, but they represent one of the first clinical signals for next‑generation gene therapy approaches in CF.